GSK sets aside £2.2bn to cover Avandia claims

Legal bills related to diabetes drug will wipe out profits for the past quarter

Glaxosmithkline is to put aside £2.2bn to cover legal costs partly stemming from claims related to its diabetes drug Avandia.

The legal charge, which will be recorded in results for the final three months of 2010, will in effect wipe out the pharmaceutical giant's quarterly profits. Analysts had expected the FTSE 100-listed drug maker to book net income of £1.45bn for the three months to December – less than the £1.8bn post-tax cost of the legal charge announced last night.

Besides covering claims related to Avandia, the provision also covers an investigation by the US Attorney's Office for the District of Colorado into GSK's sales and promotional practices for a range of drugs.

The provision comes less than a year after GSK took a £1.57bn hit for the second quarter of 2010.

"We recognise that this is a significant charge, but we believe the approach we are taking to resolve long stand legal matters is in the company's best interest," GSK's senior vice president, global litigation, PD Villarreal, said. "We have closed out a number of major cases over the last year and we remain determined to do all we can to reduce our litigation risk."

The second-quarter charge was also partly based on claims surrounding Avandia. At the time, GSK said it had settled the "substantial majority" of cases related to the controversial drug.

But it has continue to receive numerous new claims against the treatment, which was once the company's second best selling product with sales of around $3bn a year.

"As previously stated, the company has continued to receive new product liability cases regarding Avandia in the United States," GSK said. "The number of new claims received is substantial and the group has now completed its assessment of these additional cases and an estimate of likely future claims".

Avandia sales have been declining since an article by the Cleveland cardiologist Steven Nissen in The New England Journal of Medicine first cast doubt over the drug's safety.

Last year, European regulators recommended that the treatment should be withdrawn after scientific studies discovered a link between Avandia and an increased risk of heart attacks.

The drug remains on sale in the US, however, where regulators decided against a suspension, but imposed restrictions.

For its part, GSK, which said it would work with both sets of regulators and abide by their norms, continues to stand by Avandia, which brought in £391m in total sales for the nine months to September last year.

The US accounted for £197m in sales for the drug, whose US patents are due to expire in 2012. Avandia's European patents are scheduled to run out a year later in 2013.

GSK shares fell by 20p to close at 1,205p following news of the fourth quarter charge. Earlier, they had risen by as much as 1.3 per cent. The wider European pharmaceuticals sector, on other hand, closed with gains of 0.7 per cent on the day.

"The fact that this has come two quarters after the previous one will make people worry... but it doesn't change the underlying progress the company is making," Evolution Securities' analyst Dominic Valder said.

"There is a new chief financial officer just starting and there is a clear trend in the underlying profitability for the company as a new portfolio of products starts to dominate growth, so now is an obvious time to try and clean up the beast," Mr Valder added, referring to Simon Dingemans, the former Goldman Sachs banker who is due to take over from the current finance chief, Julian Heslop when he retires in March.

Analysts at Credit Suisse said most of the £2.2bn charge was likely to be related to the District of Colorado investigation, which has also hit other drug companies.

"We believe that over half of the £2.2bn legal charge is related to the investigation by the US Attorney's Office ... This investigation has been ongoing since 2004.

"Other pharmaceutical companies have been investigation and some have paid fines already," they said. "GSK had already provisioned for Colorado but the latest discussions have led to the need for higher provision."

PROMOTED VIDEO
News
ebooksAn evocation of the conflict through the eyes of those who lived through it
Life and Style
techApp to start sending headlines, TV clips and ads to your phone
Arts and Entertainment
Taylor Swift crawls through the legs of twerking dancers in her 'Shake It Off' music video
musicEarl Sweatshirt thinks so
Life and Style
tech
Arts and Entertainment
Daniel Radcliffe and Zoe Kazan in What If
filmReview: Actor swaps Harry Potter for Cary Grant in What If
News
Our resilience to stress is to a large extent determined by our genes
science
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Asset Finance Solicitor

Highly Competitive Salary: Austen Lloyd: CITY - ASSET FINANCE - An outstanding...

HR Analyst - Banking - Bristol - £350-£400

£350 - £400 per day: Orgtel: HR Analyst - Banking - Bristol - £350 - £400 per ...

Techincal Accountant-Insurance-Bank-£550/day

£475 - £550 per day + competitive: Orgtel: Senior Technical Accountant-Insuran...

Sales Performance Manager, Gloucester - £290 p/day

£200 - £290 per annum + competitive: Orgtel: Sales Performance Manager, Key Ba...

Day In a Page

Ferguson: In the heartlands of America, a descent into madness

A descent into madness in America's heartlands

David Usborne arrived in Ferguson, Missouri to be greeted by a scene more redolent of Gaza and Afghanistan
BBC’s filming of raid at Sir Cliff’s home ‘may be result of corruption’

BBC faces corruption allegation over its Sir Cliff police raid coverage

Reporter’s relationship with police under scrutiny as DG is summoned by MPs to explain extensive live broadcast of swoop on singer’s home
Lauded therapist Harley Mille still in limbo as battle to stay in Britain drags on

Lauded therapist still in limbo as battle to stay in Britain drags on

Australian Harley Miller is as frustrated by court delays as she is with the idiosyncrasies of immigration law
Lewis Fry Richardson's weather forecasts changed the world. But could his predictions of war do the same?

Lewis Fry Richardson's weather forecasts changed the world...

But could his predictions of war do the same?
Kate Bush asks fans not to take photos at her London gigs: 'I want to have contact with the audience, not iPhones'

'I want to have contact with the audience, not iPhones'

Kate Bush asks fans not to take photos at her London gigs
Under-35s have rated gardening in their top five favourite leisure activities, but why?

Young at hort

Under-35s have rated gardening in their top five favourite leisure activities. But why are so many people are swapping sweaty clubs for leafy shrubs?
Tim Vine, winner of the Funniest Joke of the Fringe award: 'making a quip as funny as possible is an art'

Beyond a joke

Tim Vine, winner of the Funniest Joke of the Fringe award, has nigh-on 200 in his act. So how are they conceived?
The late Peter O'Toole shines in 'Katherine of Alexandria' despite illness

The late Peter O'Toole shines in 'Katherine of Alexandria' despite illness

Sadly though, the Lawrence of Arabia star is not around to lend his own critique
Wicken Fen in Cambridgeshire: The joy of camping in a wetland nature reserve and sleeping under the stars

A wild night out

Wicken Fen in Cambridgeshire offers a rare chance to camp in a wetland nature reserve
Comic Sans for Cancer exhibition: It’s the font that’s openly ridiculed for its jaunty style, but figures of fun have their fans

Comic Sans for Cancer exhibition

It’s the font that’s openly ridiculed for its jaunty style, but figures of fun have their fans
Besiktas vs Arsenal: Five things we learnt from the Champions League first-leg tie

Besiktas vs Arsenal

Five things we learnt from the Champions League first-leg tie
Rory McIlroy a smash hit on the US talk show circuit

Rory McIlroy a smash hit on the US talk show circuit

As the Northern Irishman prepares for the Barclays, he finds time to appear on TV in the States, where he’s now such a global superstar that he needs no introduction
Boy racer Max Verstappen stays relaxed over step up to Formula One

Boy racer Max Verstappen stays relaxed over step up to F1

The 16-year-old will become the sport’s youngest-ever driver when he makes his debut for Toro Rosso next season
Fear brings the enemies of Isis together at last

Fear brings the enemies of Isis together at last

But belated attempts to unite will be to no avail if the Sunni caliphate remains strong in Syria, says Patrick Cockburn
Charlie Gilmour: 'I wondered if I would end up killing myself in jail'

Charlie Gilmour: 'I wondered if I'd end up killing myself in jail'

Following last week's report on prison suicides, the former inmate asks how much progress we have made in the 50 years since the abolition of capital punishment